SISTERS Data Could Lift Medtronic's SynchroMed II From Recall Repercussions

The published results of the SISTERS trial demonstrate intrathecal baclofen (ITB) therapy with the recently redesigned SynchroMed II reduces spasticity-related pain and improves quality of life more than conventional medical management with oral antispastic medications in post-stroke patients suffering spasticity. The company hopes these results can boost interest in ITB and the SynchroMed II system while it works to resolve a 2015 consent decree with the FDA related to malfunctions with a previous version of the device.